SCHEMBL16445571

SCHEMBL16445571

CN(c1nc(Nc2ccc(O)cc2)ncc1Cl)C1CCCO1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.48
TNK2 Q07912 10/20 0.47
JAK2 O60674 2/20 0.43
JAK1 P23458 1/20 0.43
LCK P06239 3/20 0.42
CHEK1 O14757 1/20 0.42
ABL1 P00519 1/20 0.42
ROS1 P08922 1/20 0.42
FGFR1 P11362 1/20 0.42
SRC P12931 1/20 0.42
TYK2 P29597 1/20 0.42
ALK Q9UM73 1/20 0.42
JAK3 P52333 3/20 0.40
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
CCND2 P30279 1/20 0.38
CCND3 P30281 1/20 0.38
PKMYT1 Q99640 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446062 0.88 JAK3 (0.53) AURKATNK2LCKJAK3
SCHEMBL16445883 0.87 AURKA (0.48) AURKATNK2LCKJAK3
Hydrochloric Acid SCHEMBL16445559 0.86 TNK2 (0.56) AURKATNK2LCKJAK3
SCHEMBL16446055 0.85 TNK2 (0.44) AURKATNK2JAK2JAK1LCK
SCHEMBL16445767 0.85 TNK2 (0.44) AURKATNK2JAK2JAK1LCK
SCHEMBL16445772 0.85 TNK2 (0.44) AURKATNK2JAK2JAK1LCK
SCHEMBL16445556 0.84 TNK2 (0.42) AURKATNK2JAK2JAK1LCK
SCHEMBL16445938 0.84 TNK2 (0.42) AURKATNK2JAK2JAK1LCK
SCHEMBL16446431 0.84 TNK2 (0.42) AURKATNK2JAK2JAK1LCK
SCHEMBL16445393 0.82 FGFR1 (0.45) TNK2JAK2JAK1LCKCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017478-B2 Inhibitors of ACK1/TNK2 tyrosine kinase H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2018-07-10 US disclosed
US-20180155297-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2018-06-07 US disclosed
US-9850216-B2 Inhibitors of ACK1/TNK2 tyrosine kinase H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2017-12-26 US disclosed
US-20160176826-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-23 US disclosed
EP-3030241-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) 2016-06-15 EP disclosed
WO-2015021149-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176826-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNNI3K, TNK2 AURKA 154/4885TNK2 3/4885JAK2 597/4885
US-10017478-B2 Inhibitors of ACK1/TNK2 tyrosine kinase TNK1, TNNI3K, TNK2 AURKA 154/4885TNK2 3/4885JAK2 597/4885
US-20180155297-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNNI3K, TNK2 AURKA 154/4885TNK2 3/4885JAK2 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.